Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

INCLUSION CRITERIA:

   - Diagnosis of peripheral T-cell or natural killer cell neoplasm

      - Any stage disease allowed

      - HTLV-positive tumors allowed

   - At least one objective measurable disease parameter. Abnormal positron emission
   tomography scans are not considered evidence of measurable disease unless results are
   confirmed by CT scan or other appropriate imaging techniques

   - Age 18 and over

   - ECOG Performance status 0-2

   - Absolute neutrophil count ≥ 1,000/mm^3(500/mm^3 if due to bone marrow involvement with
   lymphoma)

   - Platelet count ≥ 100,000/mm^3(50,000/mm^3 if due to bone marrow involvement with
   lymphoma)

   - Bilirubin ≤ 2.0 mg/dL (≤ 3 times upper limit of normal [ULN] if due to hepatic
   involvement with lymphoma)

   - AST ≤ 2 times ULN (5 times ULN if due to hepatic involvement with lymphoma)

   - PT, INR, and PTT ≤ 1.5 times normal

   - Creatinine ≤ 2.0 mg/dL

   - Urinary protein:creatinine ratio ≤ 1

   - History of deep venous thrombosis allowed provided patient is on a stable dose of
   anticoagulants for at least 2 weeks prior to study entry

   - LVEF ≥ 50%

   - History of pulmonary embolism allowed provided patient is on a stable dose of
   anticoagulants for at least 2 weeks prior to study entry

   - One prior cycle of CHOP for PTCL allowed

   - More than 4 weeks since prior major invasive surgery or open biopsy

   - At least 7 days since prior minor surgery. Peripheral lymph node core biopsy, bone
   marrow biopsy, fine needle aspiration, skin biopsy, or central line placement are not
   considered minor surgical procedures

   - More than 7 days since prior and no concurrent anti-platelet drugs (e.g., ticlopidine,
   clopidogrel, or cilostazol) except aspirin or other nonsteroidal anti-inflammatory
   drugs

   - Concurrent anticoagulants allowed provided patient is on a stable dose

      - INR must be stable for at least 2 weeks prior to study entry

      - PT/INR and/or PTT must be closely monitored and levels kept within acceptable
      range for underlying thrombotic disease

      - Concurrent heparin flush for maintenance of central line patency allowed

EXCLUSION CRITERIA:

   - Anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma. ALK-negative
   T-cell large cell lymphoma allowed

   - Cutaneous T-cell lymphoma

   - History of or current radiographic evidence of CNS metastasis, including previously
   treated, resected, or asymptomatic brain lesions or leptomeningeal involvement

   - Evidence of bleeding diathesis or coagulopathy

   - Cerebrovascular accident within the past 6 months

   - Myocardial infarction within the past 6 months

   - Unstable angina within the past 6 months

   - New York Heart Association class II-IV congestive heart failure

   - Uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic
   BP > 100 mm Hg)

   - Other clinically significant cardiovascular or peripheral vascular disease

   - Abdominal fistula within the past 6 months

   - Gastrointestinal perforation within the past 6 months

   - Intra-abdominal abscess within the past 6 months

   - Concurrent major surgery

   - Pregnant or nursing. Female patients must have negative pregnancy test. Fertile
   patients must use effective contraception

   - History of active seizures

   - Significant traumatic injury within the past 4 weeks

   - Non-healing ulcer (unless involved with lymphoma)

   - Bone fracture

   - Active infection requiring parenteral antibiotics

   - HIV positivity

   - Other active malignancy within the past 6 months except carcinoma in situ of the
   cervix or basal cell carcinoma of the skin